Renal cell carcinoma presenting as acute pancreatitis and GI bleeding

1983 ◽  
Vol 22 (4) ◽  
pp. 265-268 ◽  
Author(s):  
Joseph M. Klausner ◽  
Roland R. Rozin ◽  
Shlomo Lelcuck ◽  
Bianka Ilie
1983 ◽  
Vol 130 (4) ◽  
pp. 829-829
Author(s):  
J.M. Klausner ◽  
R.R. Rozin ◽  
S. Lelcuck ◽  
B. Ilie

2002 ◽  
Vol 68 (3) ◽  
pp. 202-203 ◽  
Author(s):  
G. Nabi ◽  
P.N. Dogra ◽  
Ashmeet Chowdhary

2021 ◽  
pp. 107815522110407
Author(s):  
Oktay Unsal ◽  
Osman Sütcüoğlu ◽  
Ozan Yazıcı

Introduction Acute pancreatitis associated with Pazopanib has been reported in the literature. Bitter Melon (Momordica Charantia) is traditionally used as a folk medicine in many regions. In this report, we describe a 65-year-old patient with a diagnosis of renal cell carcinoma, admitted to the hospital with symptoms of acute pancreatitis at the 8th year of pazopanib treatment. Case Report The patient diagnosed with renal cell carcinoma was admitted to the hospital with the complaint of abdominal pain, nausea, and vomiting in the 8th year of Pazopanib treatment. It was noticed from the patient's history that he had received Bitter Melon extract for 4 days prior to the beginning of his complaints (100–150 ml/day). Levels of serum amylase and lipase were measured as 9163 U/L and 14,206 U/L, respectively. Management & Outcome Pazopanib drug was held. The patient was treated for acute pancreatitis. Pazopanib treatment was started again after the clinical condition of the patient had improved and levels of serum amylase and lipase had returned to normal levels. Levels of serum amylase and lipase did not increase again after re-administration of pazopanib treatment. Discussion It is thought that Bitter Melon extract and pazopanib interaction might have led to acute pancreatitis. To the best of our knowledge, this case is the first to highlight the interaction of Bitter Melon extract with pazopanib. The Drug Interaction Probability Scale indicates that there is a probable association between bitter melon and acute pancreatitis.


2017 ◽  
Vol 7 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Jessica L. Mueller ◽  
Richard A. Guyer ◽  
Joel T. Adler ◽  
John T. Mullen

2016 ◽  
Vol 2 (2-3) ◽  
pp. 63-65 ◽  
Author(s):  
Utku Oflazoglu ◽  
Umut Varol ◽  
Ahmet Alacacioglu ◽  
Tarik Salman ◽  
Necla Demir ◽  
...  

2009 ◽  
Vol 42 (12) ◽  
pp. 1837-1842
Author(s):  
Toshimichi Asano ◽  
Kazuhiro Iwai ◽  
Kazuaki Hazama ◽  
Ryosuke Kawasaki ◽  
Seiji Mega

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Anastasios Katsourakis ◽  
George Noussios ◽  
Iosif Hadjis ◽  
Michael Alatsakis ◽  
Efthimios Chatzitheoklitos

We report a case of a 70-year-old man with renal cell carcinoma and metastasis to the pancreas. Symptomatic patients usually present with obstructive jaundice, abdominal pain, or GI bleeding. The diagnosis usually occurs in asymptomatic patients during followup for renal cell carcinoma. It usually befalls slowly from 2 to 18 years after the onset of the primary tumor of the kidney. A 70-year-old man presented in our department with weight loss, anorexia, and elevated blood glucose, having a large tumor on the head of the pancreas treated successfully by pancreatoduodenectomy. Three years after his treatment, the patient is doing well and without recurrence of the tumor. In conclusion, metastasis of renal cell carcinoma to the pancreas is a rare neoplasm accounting for 0.25–3% of all pancreatic tumors.


Sign in / Sign up

Export Citation Format

Share Document